GSK's Witty Weighs In On Novo Nordisk Action

Andrew Witty, head of GlaxoSmithKline (GSK), has publicly criticised Novo Nordisk for withdrawing products from Greece, following the introduction of a new pricing mechanism for pharmaceuticals.[1] Speaking at the European Federation of Pharmaceutical Industries and Association (EFPIA) annual meeting, of which he is president, Witty stated that Novo Nordisk's action "isn't necessarily helpful to the debate that is going on at the moment". Despite irritating a leading CEO, Novo Nordisk's actions resulted in concessions from the Greek government, with new prices and a consequent resumption of

To read the full article, please choose one of the following options: